The second stage of registration of the original antiparasitic drug “Sausalin” has been successfully completed
The substance of original antiparasitic drug “Sausalin” has been registered by Ministry of Health of the Republic of Kazakhstan (registration certificate No. RK-LS-5 No. 025086 dated July 15, 2021). Thus, Karaganda Pharmaceutical Plant has successfully registered the raw materials from which the drug is developed, as well as the substance. Next is the final stage - registration of the finished dosage form.
In JSC “International Research and Production Holding “Phytochemistry” the new Kazakhstani drug “Sausalin” has been developed on the basis of biologically active terpenoids of Saussurea salsa (Pall.) Spreng., and has an anti-lambliosis and anti-opisthorchiasis effect. The pharmacologically active substance of “Sausalin” is sesquiterpene lactone cynaropicrin.
“Sausalin” is characterized by high safety in its use. As shown by three phases of clinical studies of deterioration in general condition and well-being, no side effects were identified. “Sausalin” does not affect the excretory function of kidneys and liver, the composition of the normal microflora of the large intestine, does not have a local irritation effect. According to the results of preclinical and clinical studies of the drug “Sausalin”, the effectiveness of its use in the treatment of chronic opisthorchiasis was established. “Sausalin” has shown a relatively high specific activity (97.5%) than the reference drug “Biltricide” (Bayer, Germany).
The use of the drug “Sausalin” allows to achieve the eradication of lamblia in 98.6% of patients in comparison with the reference drug “Ornisid” («Abdi Ibrahim», Turkey).
The method of obtaining the antiparasitic drug “Sausalin” is protected by the Eurasian patent No. 023377.
The drug “Sausalin, 0.12g tablets” is produced by LLP “Karaganda Pharmaceutical Plant” on the basis of high-tech original technology.
 |
 |